National Institutes of Health/Contracts:
R50 NCI Research Specialist Award - National Cancer Institute
Advancing Novel Therapeutics and Translational Science to Close the Survivorship Gap in Pediatric and Adolescent and Young Adult (AYA) Lymphoma
Role: PI
NIH-R03CA259665-01
Understanding the Impact of the Affordable Care Act on Cancer Treatment and Outcomes for Adolescents and Young Adults (AYA)
Role: Co-PI
PI: Ji
NIH-U01CA246567
Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
Role: Co-I
PI: Landier/Klosky
U48DP006377-02-00
SIP 20-004. Effect of Survivorship Care Plans on Cancer Mortality
Role: Co-I
PI: Mertens/Kegler
COG-U10CA98543 - 12/1/2014-Present
AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
Role: Study Chair
PI: Adamson
Previous Funding
SurvivorLink - 10/1/2018-9/30/2023
Scalability of an Electronic Personal Health Record for Cancer Survivors and Caregivers at Pediatric Cancer Centers
Role: Advisory Board
Co-PI: Mertens/Escoffery
K07CA211956-01A1 - 09/21/2017-08/31/2022
The goal of this project is to use electronic medical record (EMR) data to capture adverse events of therapy for pediatric cancer at two large children’s hospitals and to use EMR data to describe the incidence and risk factors of acute kidney injury in children receiving therapy to treat leukemia.
Role: Mentor Team
PI: Tamara Miller
K07CA211956-01A1 - 09/21/2017-08/31/2022
The goal of this project is to use electronic medical record (EMR) data to capture adverse events of therapy for pediatric cancer at two large children’s hospitals and to use EMR data to describe the incidence and risk factors of acute kidney injury in children receiving therapy to treat leukemia.
Role: Mentor Team
PI: Tamara Miller
CURE Childhood Cancer - 7/1/2017-6/30/2022
Aflac Precision Medicine: An investigation to create a systematic institutional approach to seek novel molecular abnormalities and potential therapy targets for all high risk cancer patients from diagnosis onward
Role: Co-I; Protocol Vice-Chair
PI: Graham
Bristol-Myers Squibb - 1/2016-10/1/2019
1LETKI: Late Effects after Tyrosine Kinase Inhibitor Therapy in children and adolescents
Role: Mentor/CoPI